Diabetes Clinic, Heart and Diabetes Center NR, Ruhr University Bochum, Bad Oeynhausen, Germany.
Diabetes Technol Ther. 2013 Sep;15(9):733-7. doi: 10.1089/dia.2013.0103. Epub 2013 Aug 21.
Measurements of skin autofluorescence (SAF) allow for a simple and noninvasive quantification of tissue advanced glycation end-products (AGEs), a marker linked to the risk of diabetes complications. The aim of this study was to test the repeatability of SAF over 6 and 12 weeks and to test whether benfotiamine, a thiamine prodrug suggested to reduce AGEs formation under hyperglycemic conditions, is able to attenuate SAF when administered over 6 weeks.
In a double-blind, placebo-controlled, randomized, crossover study, 22 patients with type 2 diabetes mellitus (T2DM) received 900 mg/day benfotiamine or placebo for 6 weeks (washout period of 6 weeks between). At the beginning and at the end of each treatment period, SAF was assessed in the fasting state, as well as 2, 4, and 6 h following a mixed test meal.
The respective intra-individual and inter-individual variability of fasting SAF was 6.9% and 24.5% within 6 weeks and 10.9% and 23.1% within 12 weeks. The respective variability calculated for triplicate comparisons was 9.9% and 27.7%. A short-term therapy with benfotiamine did not influence SAF significantly, nor did we find a significant postprandial SAF increase.
In patients with T2DM, repeated, timely spaced SAF measurements have an intra-subject variability of below 11%. Using these data, sample sizes were calculated for interventional studies aiming at reducing SAF. Benfotiamine treatment for 6 weeks did not significantly influence SAF; for this, a longer-term therapy is probably needed.
皮肤 autofluorescence（SAF）的测量可实现组织晚期糖基化终产物（AGEs）的简单且非侵入性定量，AGEs 是与糖尿病并发症风险相关的标志物。本研究旨在检测 SAF 在 6 周和 12 周时的可重复性，并检验在高血糖条件下，作为减少 AGEs 形成的前体药物的苯磷硫胺，是否能够在 6 周的给药期内减弱 SAF。
在一项双盲、安慰剂对照、随机、交叉研究中，22 例 2 型糖尿病（T2DM）患者接受 900mg/天苯磷硫胺或安慰剂治疗 6 周（两次治疗期之间的洗脱期为 6 周）。在每个治疗期的开始和结束时，均在空腹状态下以及混合餐测试后 2、4 和 6 小时评估 SAF。
在 6 周内，空腹 SAF 的个体内和个体间变异性分别为 6.9%和 24.5%，在 12 周内分别为 10.9%和 23.1%。对于三次重复比较计算的变异性分别为 9.9%和 27.7%。短期苯磷硫胺治疗对 SAF 没有显著影响，我们也没有发现餐后 SAF 显著增加。
在 T2DM 患者中，重复、定时间隔的 SAF 测量具有低于 11%的个体内变异性。使用这些数据，计算了旨在降低 SAF 的干预研究的样本量。苯磷硫胺治疗 6 周对 SAF 没有显著影响；可能需要更长时间的治疗。
